Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of LM103 TILs in advanced melanoma
CTR20254771Phase 2Active
- Sponsor
- Suzhou Lanma Medical Technology Co., Ltd.
- Start
- Feb 2026
- Modality
- Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of LM103 in melanoma, sponsored by Suzhou Lanma Medical Technology Co., Ltd.. Started Feb 2026; status: active.
02
Drugs
LM103
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20254771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254771.